Hepcidin

LONG BEACH, Calif. — Researchers reported results from a phase 1b/2a placebo-controlled study of DISC-0974, an anti-hemojuvelin antibody to treat anemia in patients with chronic kidney disease.

Healio spoke with Jay B. Wish, MD, about managing anemia in patients on dialysis.

Healio spoke with Jay B. Wish, MD, about managing challenging cases of anemia.

Healio spoke with Jay B. Wish, MD, about new developments in anemia care.

In this video, Idoroenyi Amanam, MD, discussed a study presented at ASCO Annual Meeting, that looked an ALK2 inhibitor along with ruxolitinib in the treatment of anemia in myelofibrosis.

AUSTIN, Texas —An investigational treatment, DISC-0974, can reduce hepcidin and elevate iron levels in healthy patients, according to a presenter at the National Kidney Foundation Spring Clinical Meetings.

In this video, Srinivas K. Tantravahi, MBBS, MRCP(UK), highlighted phase 2 data investigating hepcidin mimetics for polycythemia vera that appears to have eliminated the need for phlebotomy.

In this video, Jay B. Wish, MD, professor of clinical medicine at Indiana University School of Medicine and chief medical officer for dialysis at Indiana University Health in Indianapolis discusses exciting new agents in the pipeline, including hypoxia-inducable factor stabilizers (HIF).